Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Organ Procurement Organization Run Department of Motor Vehicle Registration and Drivers Licensing Offices Leads to Increased Organ Donor First Person Authorization Registrations.

Dageforde LA, Muren W, Chang SH, Vachharajani N, Brockmeier D, Yu J, Anderson B, Shenoy S, Lin Y, Khan A, Wellen J, Chapman W, Doyle M.

Transplantation. 2019 Jun 24. doi: 10.1097/TP.0000000000002842. [Epub ahead of print]

PMID:
31283685
2.

Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation.

Lentine KL, Naik AS, Schnitzler MA, Randall H, Wellen JR, Kasiske BL, Marklin G, Brockmeier D, Cooper M, Xiao H, Zhang Z, Gaston RS, Rothweiler R, Axelrod DA.

Am J Transplant. 2019 Aug;19(8):2241-2251. doi: 10.1111/ajt.15325. Epub 2019 Apr 12.

PMID:
30809941
3.

Unintended consequences of changes to lung allocation policy.

Puri V, Hachem RR, Frye CC, Harrison MS, Semenkovich TR, Lynch JP, Ridolfi G, Rowe C, Meyers BF, Patterson GA, Kozower BD, Pasque MK, Nava RG, Marklin GF, Brockmeier D, Sweet SC, Chapman WC, Kreisel D.

Am J Transplant. 2019 Aug;19(8):2164-2167. doi: 10.1111/ajt.15307. Epub 2019 Mar 18.

PMID:
30758137
4.

Organ procurement center allows for daytime liver transplantation with less resource utilization: May address burnout, pipeline, and safety for field of transplantation.

Lindemann J, Dageforde LA, Brockmeier D, Vachharajani N, Scherer M, Chapman W, Doyle MBM.

Am J Transplant. 2019 May;19(5):1296-1304. doi: 10.1111/ajt.15129. Epub 2018 Oct 19.

PMID:
30247814
5.

Cost Evaluation of a Donation after Cardiac Death Program: How Cost per Organ Compares to Other Donor Types.

Lindemann J, Dageforde LA, Vachharajani N, Stahlschmidt E, Brockmeier D, Wellen JR, Khan A, Chapman WC, Doyle MM.

J Am Coll Surg. 2018 May;226(5):909-916. doi: 10.1016/j.jamcollsurg.2018.02.005. Epub 2018 Mar 2.

PMID:
29505825
6.

Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA.

Sci Immunol. 2017 Apr 21;2(10). pii: eaai7616. doi: 10.1126/sciimmunol.aai7616.

7.

Organ Donor Recovery Performed at an Organ Procurement Organization-Based Facility Is an Effective Way to Minimize Organ Recovery Costs and Increase Organ Yield.

Doyle M, Subramanian V, Vachharajani N, Collins K, Wellen JR, Stahlschmidt E, Brockmeier D, Coleman J, Kappel D, Chapman WC.

J Am Coll Surg. 2016 Apr;222(4):591-600. doi: 10.1016/j.jamcollsurg.2015.12.032. Epub 2016 Feb 29.

PMID:
26947113
8.

A novel organ donor facility: a decade of experience with liver donors.

Doyle MB, Vachharajani N, Wellen JR, Lowell JA, Shenoy S, Ridolfi G, Jendrisak MD, Coleman J, Maher M, Brockmeier D, Kappel D, Chapman WC.

Am J Transplant. 2014 Mar;14(3):615-20.

9.

Comparison of high- and low-dose corticosteroid regimens for organ donor management.

Dhar R, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, Wright R.

J Crit Care. 2013 Feb;28(1):111.e1-7. doi: 10.1016/j.jcrc.2012.04.015. Epub 2012 Jul 2.

PMID:
22762934
10.

Why Escherichia coli alpha-hemolysin induces calcium oscillations in mammalian cells--the pore is on its own.

Koschinski A, Repp H, Unver B, Dreyer F, Brockmeier D, Valeva A, Bhakdi S, Walev I.

FASEB J. 2006 May;20(7):973-5. Epub 2006 Apr 5.

PMID:
16597673
11.

Altruistic living donors: evaluation for nondirected kidney or liver donation.

Jendrisak MD, Hong B, Shenoy S, Lowell J, Desai N, Chapman W, Vijayan A, Wetzel RD, Smith M, Wagner J, Brennan S, Brockmeier D, Kappel D.

Am J Transplant. 2006 Jan;6(1):115-20.

12.

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.

Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M.

Pharmacogenetics. 2004 Jul;14(7):407-17.

PMID:
15226673
13.

Investigation on interaction between tacrolimus and sildenafil in kidney-transplanted patients with erectile dysfunction.

Christ B, Brockmeier D, Hauck EW, Kamali-Ernst S.

Int J Clin Pharmacol Ther. 2004 Mar;42(3):149-56.

PMID:
15049434
14.

Listeriolysin of Listeria monocytogenes forms Ca2+-permeable pores leading to intracellular Ca2+ oscillations.

Repp H, Pamukçi Z, Koschinski A, Domann E, Darji A, Birringer J, Brockmeier D, Chakraborty T, Dreyer F.

Cell Microbiol. 2002 Aug;4(8):483-91.

PMID:
12174083
15.

Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation.

Christ B, Brockmeier D, Hauck EW, Friemann S.

Urology. 2001 Oct;58(4):589-93.

PMID:
11597545
16.

Mean time concept and component analysis in pharmacokinetics.

Brockmeier D.

Int J Clin Pharmacol Ther. 1999 Nov;37(11):555-61. Review.

PMID:
10584977
17.

Tight binding influencing the future of pharmacokinetics.

Brockmeier D.

Methods Find Exp Clin Pharmacol. 1998 Jul-Aug;20(6):505-16. Review. No abstract available.

PMID:
9789874
18.

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.

Schrenk D, Brockmeier D, Mörike K, Bock KW, Eichelbaum M.

Eur J Clin Pharmacol. 1998 Jan;53(5):361-7.

PMID:
9516038
19.
20.

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Bock KW, Schrenk D, Forster A, Griese EU, Mörike K, Brockmeier D, Eichelbaum M.

Pharmacogenetics. 1994 Aug;4(4):209-18.

PMID:
7987405
21.

Characterization of cyclosporine A uptake in human erythrocytes.

Reichel C, von Falkenhausen M, Brockmeier D, Dengler HJ.

Eur J Clin Pharmacol. 1994;46(5):417-9.

PMID:
7957535
22.
23.

Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.

Heintz B, Verho M, Brockmeier D, Lückel G, Maigatter S, Sieberth HG, Rangoonwala B, Bender N.

J Cardiovasc Pharmacol. 1993;22 Suppl 9:S36-42.

PMID:
7514239
24.

Pharmacokinetic profile of cefodizime.

Brockmeier D, Dagrosa EE.

Infection. 1992;20 Suppl 1:S14-7. Review.

PMID:
1526669
25.

Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Rietbrock S, Keller-Stanislawski B, Thürmann P, Brockmeier D.

Eur J Clin Pharmacol. 1992;43(3):273-6.

PMID:
1425891
26.

Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.

Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Rangoonwala B, Maigatter S, Lückel G, Kierdorf H, Sieberth HG.

Clin Physiol Biochem. 1992;9(3):113-8.

PMID:
1302161
27.

Influence of ramipril on renal function in patients with chronic congestive heart failure.

Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefèvre G, Kierdorf H, Sieberth HG.

J Cardiovasc Pharmacol. 1991;18 Suppl 2:S174-9.

PMID:
1725035
28.

Evidence for muscarinic receptors in endothelial cells from combined functional and binding studies.

Brunner F, Kühberger E, Brockmeier D, Kukovetz WR.

Eur J Pharmacol. 1990 Oct 9;187(2):145-54.

PMID:
2272358
29.

Pharmacokinetics of prenylamine racemate and enantiomers in man.

Paar WD, Brockmeier D, Hirzebruch M, Schmidt EK, von Unruh GE, Dengler HJ.

Arzneimittelforschung. 1990 Jun;40(6):657-61.

PMID:
2397000
30.

Pharmacokinetic characteristics of roxatidine.

Bender W, Brockmeier D.

J Clin Gastroenterol. 1989;11 Suppl 1:S6-19. Review.

PMID:
2572622
31.
32.

Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.

Brockmeier D, Hajdù P, Henke W, Mutschler E, Palm D, Rupp W, Spahn H, Verho MT, Wellstein A.

Eur J Clin Pharmacol. 1988;35(6):613-23.

PMID:
2906875
33.

Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.

Lameire N, Rosenkranz B, Brockmeier D.

Scand J Gastroenterol Suppl. 1988;146:100-10. Review.

PMID:
2906455
34.

A pharmacokinetic study of roxatidine acetate in chronic renal failure.

Lameire N, Rosenkranz B, Maass L, Brockmeier D.

Drugs. 1988;35 Suppl 3:48-52.

PMID:
2905249
35.

Kinetics of piretanide absorption from the gastrointestinal tract.

Brockmeier D, Grigoleit HG, Heptner H, Meyer BH.

Methods Find Exp Clin Pharmacol. 1986 Dec;8(12):731-9.

PMID:
3807474
36.

Model-free evaluation and mean-time concept in pharmacokinetics.

Brockmeier D.

Methods Find Exp Clin Pharmacol. 1986 Oct;8(10):593-602.

PMID:
3784698
37.

Mean residence time.

Brockmeier D, von Hattingberg HM.

Methods Find Exp Clin Pharmacol. 1986 May;8(5):309-12.

PMID:
3724305
38.

The absorption of piretanide from the gastro-intestinal tract is site-dependent.

Brockmeier D, Grigoleit HG, Leonhardt H.

Eur J Clin Pharmacol. 1986;30(1):79-82.

PMID:
3709635
39.

Presystemic elimination and mean residence time.

Brockmeier D.

Biopharm Drug Dispos. 1985 Apr-Jun;6(2):229-30. No abstract available.

PMID:
4005399
41.

Absorption of glibenclamide from different sites of the gastro-intestinal tract.

Brockmeier D, Grigoleit HG, Leonhardt H.

Eur J Clin Pharmacol. 1985;29(2):193-7.

PMID:
3935463
42.

Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.

Ostrowski J, Gaul G, Voegele D, Brockmeier D, Resag K.

Eur J Clin Pharmacol. 1985;28(5):611-3.

PMID:
3899679
43.

Mean time and first-pass metabolism.

Brockmeier D, Ostrowski J.

Eur J Clin Pharmacol. 1985;29(1):45-8.

PMID:
3840437
44.

In vitro-in vivo correlation, a time scaling problem? Evaluation of mean times.

Brockmeier D.

Arzneimittelforschung. 1984;34(11):1604-7.

PMID:
6543138
45.

[Pharmacokinetic aspects of excretory urography in children].

Klingmüller V, Brockmeier D, Schuster W, von Hattingberg HM.

Rofo. 1983 Mar;138(3):316-22. German.

PMID:
6403426
46.

[The determination of pharmacokinetic parameters from surveillance protocols of sepsis therapy].

von Hattingberg HM, Roos R, Brockmeier D, Marget W.

Internist (Berl). 1983 Mar;24(3):162-6. German. No abstract available.

PMID:
6347942
47.

In vitro--in vivo correlation, a time scaling problem? Basic techniques for testing equivalence.

Brockmeier D, Voegele D, von Hattingberg HM.

Arzneimittelforschung. 1983;33(4):598-601. No abstract available.

PMID:
6683542
48.

Properties of agonist binding at the beta-adrenoceptor of the rat reticulocyte.

Wiemer G, Wellstein A, Palm D, von Hattingberg HM, Brockmeier D.

Naunyn Schmiedebergs Arch Pharmacol. 1982 Oct;321(1):11-9. No abstract available.

PMID:
6128680
49.

In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.

Brockmeier D, von Hattingberg HM.

Arzneimittelforschung. 1982;32(3):248-51.

PMID:
6896279
50.

Supplemental Content

Loading ...
Support Center